Summary
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Hereditary Angioedema Drug market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Hereditary Angioedema Drug market segmented into
By Product
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Route of Administration
Oral
Intravenous
Subcutaneous Injection
Based on the end-use, the global Hereditary Angioedema Drug market classified into
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Based on geography, the global Hereditary Angioedema Drug market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Pharming Group NV
Shire plc
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Hereditary Angioedema Drug market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Hereditary Angioedema Drug market segmented into
By Product
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Route of Administration
Oral
Intravenous
Subcutaneous Injection
Based on the end-use, the global Hereditary Angioedema Drug market classified into
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Based on geography, the global Hereditary Angioedema Drug market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Pharming Group NV
Shire plc
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL HEREDITARY ANGIOEDEMA DRUG INDUSTRY
2.1 Summary about Hereditary Angioedema Drug Industry
2.2 Hereditary Angioedema Drug Market Trends
2.2.1 Hereditary Angioedema Drug Production & Consumption Trends
2.2.2 Hereditary Angioedema Drug Demand Structure Trends
2.3 Hereditary Angioedema Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 By Product
4.2.2 C1 Esterase Inhibitor
4.2.3 Kallikrein Inhibitor
4.2.4 Selective Bradykinin B2 Receptor Antagonist
4.2.5 By Route of Administration
4.2.6 Oral
4.2.7 Intravenous
4.2.8 Subcutaneous Injection
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Retail Pharmacies
4.3.2 Hospital Pharmacies
4.3.3 Online Pharmacies
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 By Product
5.2.2 C1 Esterase Inhibitor
5.2.3 Kallikrein Inhibitor
5.2.4 Selective Bradykinin B2 Receptor Antagonist
5.2.5 By Route of Administration
5.2.6 Oral
5.2.7 Intravenous
5.2.8 Subcutaneous Injection
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Retail Pharmacies
5.3.2 Hospital Pharmacies
5.3.3 Online Pharmacies
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 By Product
6.2.2 C1 Esterase Inhibitor
6.2.3 Kallikrein Inhibitor
6.2.4 Selective Bradykinin B2 Receptor Antagonist
6.2.5 By Route of Administration
6.2.6 Oral
6.2.7 Intravenous
6.2.8 Subcutaneous Injection
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Retail Pharmacies
6.3.2 Hospital Pharmacies
6.3.3 Online Pharmacies
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 By Product
7.2.2 C1 Esterase Inhibitor
7.2.3 Kallikrein Inhibitor
7.2.4 Selective Bradykinin B2 Receptor Antagonist
7.2.5 By Route of Administration
7.2.6 Oral
7.2.7 Intravenous
7.2.8 Subcutaneous Injection
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Retail Pharmacies
7.3.2 Hospital Pharmacies
7.3.3 Online Pharmacies
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 By Product
8.2.2 C1 Esterase Inhibitor
8.2.3 Kallikrein Inhibitor
8.2.4 Selective Bradykinin B2 Receptor Antagonist
8.2.5 By Route of Administration
8.2.6 Oral
8.2.7 Intravenous
8.2.8 Subcutaneous Injection
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Retail Pharmacies
8.3.2 Hospital Pharmacies
8.3.3 Online Pharmacies
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 By Product
9.2.2 C1 Esterase Inhibitor
9.2.3 Kallikrein Inhibitor
9.2.4 Selective Bradykinin B2 Receptor Antagonist
9.2.5 By Route of Administration
9.2.6 Oral
9.2.7 Intravenous
9.2.8 Subcutaneous Injection
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Retail Pharmacies
9.3.2 Hospital Pharmacies
9.3.3 Online Pharmacies
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Pharming Group NV
10.1.2 Shire plc
10.1.3 CSL Limited
10.1.4 iBio Inc.
10.1.5 BioCryst Pharmaceuticals, Inc.
10.1.6 Ionis Pharmaceuticals, Inc.
10.2 Hereditary Angioedema Drug Sales Date of Major Players (2017-2020e)
10.2.1 Pharming Group NV
10.2.2 Shire plc
10.2.3 CSL Limited
10.2.4 iBio Inc.
10.2.5 BioCryst Pharmaceuticals, Inc.
10.2.6 Ionis Pharmaceuticals, Inc.
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL HEREDITARY ANGIOEDEMA DRUG INDUSTRY
2.1 Summary about Hereditary Angioedema Drug Industry
2.2 Hereditary Angioedema Drug Market Trends
2.2.1 Hereditary Angioedema Drug Production & Consumption Trends
2.2.2 Hereditary Angioedema Drug Demand Structure Trends
2.3 Hereditary Angioedema Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 By Product
4.2.2 C1 Esterase Inhibitor
4.2.3 Kallikrein Inhibitor
4.2.4 Selective Bradykinin B2 Receptor Antagonist
4.2.5 By Route of Administration
4.2.6 Oral
4.2.7 Intravenous
4.2.8 Subcutaneous Injection
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Retail Pharmacies
4.3.2 Hospital Pharmacies
4.3.3 Online Pharmacies
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 By Product
5.2.2 C1 Esterase Inhibitor
5.2.3 Kallikrein Inhibitor
5.2.4 Selective Bradykinin B2 Receptor Antagonist
5.2.5 By Route of Administration
5.2.6 Oral
5.2.7 Intravenous
5.2.8 Subcutaneous Injection
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Retail Pharmacies
5.3.2 Hospital Pharmacies
5.3.3 Online Pharmacies
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 By Product
6.2.2 C1 Esterase Inhibitor
6.2.3 Kallikrein Inhibitor
6.2.4 Selective Bradykinin B2 Receptor Antagonist
6.2.5 By Route of Administration
6.2.6 Oral
6.2.7 Intravenous
6.2.8 Subcutaneous Injection
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Retail Pharmacies
6.3.2 Hospital Pharmacies
6.3.3 Online Pharmacies
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 By Product
7.2.2 C1 Esterase Inhibitor
7.2.3 Kallikrein Inhibitor
7.2.4 Selective Bradykinin B2 Receptor Antagonist
7.2.5 By Route of Administration
7.2.6 Oral
7.2.7 Intravenous
7.2.8 Subcutaneous Injection
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Retail Pharmacies
7.3.2 Hospital Pharmacies
7.3.3 Online Pharmacies
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 By Product
8.2.2 C1 Esterase Inhibitor
8.2.3 Kallikrein Inhibitor
8.2.4 Selective Bradykinin B2 Receptor Antagonist
8.2.5 By Route of Administration
8.2.6 Oral
8.2.7 Intravenous
8.2.8 Subcutaneous Injection
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Retail Pharmacies
8.3.2 Hospital Pharmacies
8.3.3 Online Pharmacies
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 By Product
9.2.2 C1 Esterase Inhibitor
9.2.3 Kallikrein Inhibitor
9.2.4 Selective Bradykinin B2 Receptor Antagonist
9.2.5 By Route of Administration
9.2.6 Oral
9.2.7 Intravenous
9.2.8 Subcutaneous Injection
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Retail Pharmacies
9.3.2 Hospital Pharmacies
9.3.3 Online Pharmacies
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Pharming Group NV
10.1.2 Shire plc
10.1.3 CSL Limited
10.1.4 iBio Inc.
10.1.5 BioCryst Pharmaceuticals, Inc.
10.1.6 Ionis Pharmaceuticals, Inc.
10.2 Hereditary Angioedema Drug Sales Date of Major Players (2017-2020e)
10.2.1 Pharming Group NV
10.2.2 Shire plc
10.2.3 CSL Limited
10.2.4 iBio Inc.
10.2.5 BioCryst Pharmaceuticals, Inc.
10.2.6 Ionis Pharmaceuticals, Inc.
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
